Subgroup analyses help Vanda hold steady despite Phase III itch miss

Vanda shares Wednesday mostly shrugged off a sharp decline in after-hours trading Tuesday after tradipitant missed the primary endpoint in the Phase III EPIONE trial to treat atopic dermatitis in patients with severe pruritus.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had tumbled $0.87 to $10.60 in after-hours trading Tuesday, but closed down a mere $0.15 to $11.32 on Wednesday. ...